samedan logo
 
 
 
spacer
home > ebr > spring 2020 > eschewing the escalation of salaries as safety professionals grow scarcer
PUBLICATIONS
European Biopharmaceutical Review

Eschewing the Escalation of Salaries as Safety Professionals Grow Scarcer

How to retain relevant, experienced safety and regulatory talent has arguably never been higher up the list of conversation topics in life sciences than it is today, as younger professionals’ ambitions for a broad base of experience conflict with firms’ needs to hang onto the expertise they have invested in. The challenge appears to be a global one too, judging by the wide spectrum of comments at the FT Global Pharmaceutical and Biotechnology Conference in London last November. There, attendees from both sides of the Atlantic gave voice to their concerns and swapped ideas for combatting the talent shortfall and the risk of skilled practitioners moving on to seemingly greener pastures.

Biotech companies are disproportionately vulnerable, unable to match the salaries and ‘on-paper’ benefits of the global pharma giants. Too often, these more modest-sized organisations provide new graduates with a firm foundation in pharmacovigilance (PV), only for a larger brand to poach them – wooing them with a more senior version of the same role and a 20% hike in salary.

Money Isn’t Everything

There is a growing realisation among life science employers that they must come up with new and creative ways to foster and hold on to rising talent to stay competitive. Whatever the care needed when generalising about ‘millennials’ as a single category of employee, it is clear that there has been a shift in values among those in the earlier stages of their working life. As well as being hungry for a greater range of career experiences, for example, newer graduates are reputedly less influenced by salary than previous generations. Freedom to explore, create, innovate, and experiment at work are often among their personal priorities, along with the ability to protect their work-life balance, which may mean being able to apply for extended periods off work to fulfil extracurricular ambitions, work from home, or have more control over their working hours.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alan White is CEO at Arriello, a specialist global provider of innovative, high-impact market access, regulatory affairs, and pharmacovigilance solutions and services for pharma and biotech firms primarily in Europe and North America.
spacer
Alan White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up • Tailored upstream development from a single source reduces time to clinic by 20 percent • Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement